Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allogene Therapeutics, Inc.ALLO · Entity 5243 | General Counsel | March 14, 2023 | March 16, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allogene Therapeutics, Inc.
Report date March 14, 2023 · Filed March 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 556,049 |
Reported balance
After 2023-03-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-03-14 · Tax withholding · Disposed 23,628 · Balance 556,049 F1: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Includes 2,000 shares of the Issuer's common stock acquired by the reporting person on March 15, 2023 pursuant to an employee stock purchase program. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Includes 2,000 shares of the Issuer's common stock acquired by the reporting person on March 15, 2023 pursuant to an employee stock purchase program.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2020 Filed Aug 5, 2020 17:09 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001214659-20-006805 · marketforms-49403.xml · derivative · entry 4 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,800 Underlying: Common Stock · 25,000 shares Expires 2028-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:09 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 16,450 | $37.29 | $613,397.47 |
DisclosureSEC source: 0001214659-20-006805 · marketforms-49403.xml · nonDerivative · entry 3 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,902 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.95 to $37.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:09 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 15,103 | $36.46 | $550,723.34 |
DisclosureSEC source: 0001214659-20-006805 · marketforms-49403.xml · nonDerivative · entry 2 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,352 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.95 to $36.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:09 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionCommon Stock | 25,000 | $2.27 | $56,750.00 |
DisclosureSEC source: 0001214659-20-006805 · marketforms-49403.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.